[96a5a0]: / output / allTrials / identified / NCT06362291_identified.json

Download this file

610 lines (610 with data), 27.7 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
{
"info": {
"nct_id": "NCT06362291",
"official_title": "Comparison of MRI Artificial Intelligence-guided Cognitive Fusion-targeted Biopsy Versus Routine Cognitive Fusion-targeted Prostate Biopsy in Prostate Cancer Diagnosis: a Prospective Randomized Controlled Trial",
"inclusion_criteria": "1. The age of the patient is between 45 and 85.\n2. Patients with complete multiparametric magnetic resonance imaging (mpMRI) data of Peking University First Hospital, qualified image quality control, suspicious lesions, and Prostate Imaging Reporting and Data System version 2.1 (PI-RADS V2.1) of ≥ 3.\n3. Patients were in accordance with the indication of prostate biopsy, including patients with suspicious prostate nodes found by digital rectal examination (DRE), the suspicious lesions found by transrectal ultrasound (TRUS) or MRI, total prostate-specific antigen (tPSA) >10ng/mL, tPSA 4-10ng/mL with free-to-total PSA ratio (f/tPSA) <0.16 or PSA density (PSAD) >0.15.\n4. Patients were in accordance with the indication of repeated prostate biopsy (patients with atypical acinar hyperplasia or high-grade intraepithelial neoplasia, especially when the pathological results of multi-needle puncture were as above; re-examination of PSA > 10 ng/ml; re-examination of PSA 4~10ng/ml, abnormal f/tPSA, abnormal PSAD, abnormal DRE, or imaging abnormalities; for patients with the results of re-examination of PSA 4~10ng/ml and with close follow-up, PSA for 2 consecutive years > 10ng/ml or PSA volume > 0.75/ml/ years). The time interval between the two prostate biopsies should be longer than three months.\n5. The targeted prostate biopsy pathological results of above lesions were complete. The time interval between targeted prostate biopsy and prostate mpMRI examination should not exceed one month.\n6. Patients with complete clinical information.\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 45 Years\nMust have maximum age of 85 Years",
"exclusion_criteria": "1. The mpMRI data was unqualified or incomplete.\n2. Patients had received radiotherapy, chemotherapy, androgen deprivation therapy, or surgery treatment before prostate mpMRI examination or prostate biopsy.\n3. The mpMRI of Peking University First Hospital did not find suspicious prostate lesions.\n4. Patients were not in accordance with the indication of prostate biopsy or were not received systematic biopsy combined with targeted biopsy.\n5. The patient could not cooperate to complete the systematic biopsy combined with targeted biopsy. The patients or their family members refused to participate in this study.\n6. Patients with incomplete clinical information.",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "1. The age of the patient is between 45 and 85.",
"criterions": [
{
"exact_snippets": "age of the patient is between 45 and 85",
"criterion": "age",
"requirements": [
{
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 45,
"unit": "years"
},
{
"operator": "<=",
"value": 85,
"unit": "years"
}
]
}
}
]
}
]
},
{
"line": "2. Patients with complete multiparametric magnetic resonance imaging (mpMRI) data of Peking University First Hospital, qualified image quality control, suspicious lesions, and Prostate Imaging Reporting and Data System version 2.1 (PI-RADS V2.1) of ≥ 3.",
"criterions": [
{
"exact_snippets": "complete multiparametric magnetic resonance imaging (mpMRI) data",
"criterion": "mpMRI data",
"requirements": [
{
"requirement_type": "completeness",
"expected_value": true
}
]
},
{
"exact_snippets": "qualified image quality control",
"criterion": "image quality control",
"requirements": [
{
"requirement_type": "qualification",
"expected_value": true
}
]
},
{
"exact_snippets": "suspicious lesions",
"criterion": "lesions",
"requirements": [
{
"requirement_type": "suspicion",
"expected_value": true
}
]
},
{
"exact_snippets": "Prostate Imaging Reporting and Data System version 2.1 (PI-RADS V2.1) of ≥ 3",
"criterion": "PI-RADS V2.1",
"requirements": [
{
"requirement_type": "score",
"expected_value": {
"operator": ">=",
"value": 3,
"unit": "N/A"
}
}
]
}
]
},
{
"line": "3. Patients were in accordance with the indication of prostate biopsy, including patients with suspicious prostate nodes found by digital rectal examination (DRE), the suspicious lesions found by transrectal ultrasound (TRUS) or MRI, total prostate-specific antigen (tPSA) >10ng/mL, tPSA 4-10ng/mL with free-to-total PSA ratio (f/tPSA) <0.16 or PSA density (PSAD) >0.15.",
"criterions": [
{
"exact_snippets": "suspicious prostate nodes found by digital rectal examination (DRE)",
"criterion": "suspicious prostate nodes",
"requirements": [
{
"requirement_type": "detection method",
"expected_value": "digital rectal examination (DRE)"
}
]
},
{
"exact_snippets": "suspicious lesions found by transrectal ultrasound (TRUS)",
"criterion": "suspicious lesions",
"requirements": [
{
"requirement_type": "detection method",
"expected_value": "transrectal ultrasound (TRUS)"
}
]
},
{
"exact_snippets": "suspicious lesions found by ... MRI",
"criterion": "suspicious lesions",
"requirements": [
{
"requirement_type": "detection method",
"expected_value": "MRI"
}
]
},
{
"exact_snippets": "total prostate-specific antigen (tPSA) >10ng/mL",
"criterion": "total prostate-specific antigen (tPSA)",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": ">",
"value": 10,
"unit": "ng/mL"
}
}
]
},
{
"exact_snippets": "tPSA 4-10ng/mL",
"criterion": "total prostate-specific antigen (tPSA)",
"requirements": [
{
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 4,
"unit": "ng/mL"
},
{
"operator": "<=",
"value": 10,
"unit": "ng/mL"
}
]
}
}
]
},
{
"exact_snippets": "free-to-total PSA ratio (f/tPSA) <0.16",
"criterion": "free-to-total PSA ratio (f/tPSA)",
"requirements": [
{
"requirement_type": "ratio",
"expected_value": {
"operator": "<",
"value": 0.16,
"unit": "N/A"
}
}
]
},
{
"exact_snippets": "PSA density (PSAD) >0.15",
"criterion": "PSA density (PSAD)",
"requirements": [
{
"requirement_type": "density",
"expected_value": {
"operator": ">",
"value": 0.15,
"unit": "N/A"
}
}
]
}
]
},
{
"line": "4. Patients were in accordance with the indication of repeated prostate biopsy (patients with atypical acinar hyperplasia or high-grade intraepithelial neoplasia, especially when the pathological results of multi-needle puncture were as above; re-examination of PSA > 10 ng/ml; re-examination of PSA 4~10ng/ml, abnormal f/tPSA, abnormal PSAD, abnormal DRE, or imaging abnormalities; for patients with the results of re-examination of PSA 4~10ng/ml and with close follow-up, PSA for 2 consecutive years > 10ng/ml or PSA volume > 0.75/ml/ years). The time interval between the two prostate biopsies should be longer than three months.",
"criterions": [
{
"exact_snippets": "atypical acinar hyperplasia",
"criterion": "atypical acinar hyperplasia",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "high-grade intraepithelial neoplasia",
"criterion": "high-grade intraepithelial neoplasia",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "pathological results of multi-needle puncture were as above",
"criterion": "pathological results of multi-needle puncture",
"requirements": [
{
"requirement_type": "consistency",
"expected_value": "atypical acinar hyperplasia or high-grade intraepithelial neoplasia"
}
]
},
{
"exact_snippets": "re-examination of PSA > 10 ng/ml",
"criterion": "PSA level",
"requirements": [
{
"requirement_type": "value",
"expected_value": {
"operator": ">",
"value": 10,
"unit": "ng/ml"
}
}
]
},
{
"exact_snippets": "re-examination of PSA 4~10ng/ml",
"criterion": "PSA level",
"requirements": [
{
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 4,
"unit": "ng/ml"
},
{
"operator": "<=",
"value": 10,
"unit": "ng/ml"
}
]
}
}
]
},
{
"exact_snippets": "abnormal f/tPSA",
"criterion": "f/tPSA",
"requirements": [
{
"requirement_type": "status",
"expected_value": "abnormal"
}
]
},
{
"exact_snippets": "abnormal PSAD",
"criterion": "PSAD",
"requirements": [
{
"requirement_type": "status",
"expected_value": "abnormal"
}
]
},
{
"exact_snippets": "abnormal DRE",
"criterion": "DRE",
"requirements": [
{
"requirement_type": "status",
"expected_value": "abnormal"
}
]
},
{
"exact_snippets": "imaging abnormalities",
"criterion": "imaging",
"requirements": [
{
"requirement_type": "status",
"expected_value": "abnormal"
}
]
},
{
"exact_snippets": "PSA for 2 consecutive years > 10ng/ml",
"criterion": "PSA level over 2 years",
"requirements": [
{
"requirement_type": "value",
"expected_value": {
"operator": ">",
"value": 10,
"unit": "ng/ml"
}
}
]
},
{
"exact_snippets": "PSA volume > 0.75/ml/ years",
"criterion": "PSA volume",
"requirements": [
{
"requirement_type": "value",
"expected_value": {
"operator": ">",
"value": 0.75,
"unit": "ml/years"
}
}
]
},
{
"exact_snippets": "time interval between the two prostate biopsies should be longer than three months",
"criterion": "time interval between prostate biopsies",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": ">",
"value": 3,
"unit": "months"
}
}
]
}
]
},
{
"line": "5. The targeted prostate biopsy pathological results of above lesions were complete. The time interval between targeted prostate biopsy and prostate mpMRI examination should not exceed one month.",
"criterions": [
{
"exact_snippets": "The targeted prostate biopsy pathological results of above lesions were complete.",
"criterion": "targeted prostate biopsy pathological results",
"requirements": [
{
"requirement_type": "completeness",
"expected_value": true
}
]
},
{
"exact_snippets": "The time interval between targeted prostate biopsy and prostate mpMRI examination should not exceed one month.",
"criterion": "time interval between targeted prostate biopsy and prostate mpMRI examination",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": "<=",
"value": 1,
"unit": "month"
}
}
]
}
]
},
{
"line": "6. Patients with complete clinical information.",
"criterions": [
{
"exact_snippets": "complete clinical information",
"criterion": "clinical information",
"requirements": [
{
"requirement_type": "completeness",
"expected_value": true
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must be MALE",
"criterions": [
{
"exact_snippets": "MALE",
"criterion": "gender",
"requirements": [
{
"requirement_type": "expected_value",
"expected_value": "male"
}
]
}
]
},
{
"line": "Must have minimum age of 45 Years",
"criterions": [
{
"exact_snippets": "minimum age of 45 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 45,
"unit": "Years"
}
}
]
}
]
},
{
"line": "Must have maximum age of 85 Years",
"criterions": [
{
"exact_snippets": "maximum age of 85 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "maximum",
"expected_value": {
"operator": "<=",
"value": 85,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "1. The mpMRI data was unqualified or incomplete.",
"criterions": [
{
"exact_snippets": "mpMRI data was unqualified",
"criterion": "mpMRI data",
"requirements": [
{
"requirement_type": "qualification",
"expected_value": true
}
]
},
{
"exact_snippets": "mpMRI data was ... incomplete",
"criterion": "mpMRI data",
"requirements": [
{
"requirement_type": "completeness",
"expected_value": true
}
]
}
]
},
{
"line": "2. Patients had received radiotherapy, chemotherapy, androgen deprivation therapy, or surgery treatment before prostate mpMRI examination or prostate biopsy.",
"criterions": [
{
"exact_snippets": "Patients had received radiotherapy",
"criterion": "radiotherapy",
"requirements": [
{
"requirement_type": "received",
"expected_value": true
}
]
},
{
"exact_snippets": "Patients had received ... chemotherapy",
"criterion": "chemotherapy",
"requirements": [
{
"requirement_type": "received",
"expected_value": true
}
]
},
{
"exact_snippets": "Patients had received ... androgen deprivation therapy",
"criterion": "androgen deprivation therapy",
"requirements": [
{
"requirement_type": "received",
"expected_value": true
}
]
},
{
"exact_snippets": "Patients had received ... surgery treatment",
"criterion": "surgery treatment",
"requirements": [
{
"requirement_type": "received",
"expected_value": true
}
]
}
]
},
{
"line": "3. The mpMRI of Peking University First Hospital did not find suspicious prostate lesions.",
"criterions": [
{
"exact_snippets": "mpMRI of Peking University First Hospital did not find suspicious prostate lesions",
"criterion": "suspicious prostate lesions",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "4. Patients were not in accordance with the indication of prostate biopsy or were not received systematic biopsy combined with targeted biopsy.",
"criterions": [
{
"exact_snippets": "not in accordance with the indication of prostate biopsy",
"criterion": "indication of prostate biopsy",
"requirements": [
{
"requirement_type": "accordance",
"expected_value": false
}
]
},
{
"exact_snippets": "not received systematic biopsy combined with targeted biopsy",
"criterion": "systematic biopsy combined with targeted biopsy",
"requirements": [
{
"requirement_type": "receipt",
"expected_value": false
}
]
}
]
},
{
"line": "5. The patient could not cooperate to complete the systematic biopsy combined with targeted biopsy. The patients or their family members refused to participate in this study.",
"criterions": [
{
"exact_snippets": "The patient could not cooperate to complete the systematic biopsy combined with targeted biopsy.",
"criterion": "cooperation for biopsy",
"requirements": [
{
"requirement_type": "ability",
"expected_value": true
}
]
},
{
"exact_snippets": "The patients or their family members refused to participate in this study.",
"criterion": "willingness to participate",
"requirements": [
{
"requirement_type": "willingness",
"expected_value": true
}
]
}
]
},
{
"line": "6. Patients with incomplete clinical information.",
"criterions": [
{
"exact_snippets": "incomplete clinical information",
"criterion": "clinical information",
"requirements": [
{
"requirement_type": "completeness",
"expected_value": false
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}